肿瘤细胞治疗研究
英文原题：HER2-positive gastric cancer: from targeted therapy to CAR-T cell therapy.
胃癌（GC）在全球范围内的发病率位居第五，其中 HER2 阳性胃癌是一个具有更复杂生物学特征的独特亚型。
胃癌（GC）是全球第五常见癌症，其中 HER2 阳性胃癌是具有独特亚型特征的疾病，生物学特征更复杂。传统化疗治疗 HER2 阳性胃癌的疗效通常有限。随着分子靶向治疗不断进步，靶向 HER2 已成为治疗该亚型的有前景方法。抗体-药物偶联物（ADC）和CAR-T 细胞疗法的出现，为 HER2 阳性胃癌提供了新的治疗选择。然而，胃癌具有显著异质性且肿瘤微环境复杂，因此常出现耐药，显著影响 HER2 靶向治疗疗效。本文全面总结并讨论 HER2 靶向治疗策略及其潜在耐药机制。
Gastric cancer (GC) ranks as the fifth most prevalent cancer on a global scale, with HER2-positive GC representing a distinct subtype that exhibits more intricate biological characteristics. Conventional chemotherapy typically exhibits restricted efficacy in the management of HER2-positive GC. In light of the incessant advancement in molecular targeted therapies, targeting HER2 has emerged as a promising therapeutic approach for this subtype. The advent of antibody-drug conjugates (ADCs) and chimeric antigen receptor T-cell therapy (CAR-T) has furnished novel treatment alternatives for HER2-positive GC. Nevertheless, owing to the pronounced heterogeneity of GC and the complex tumor microenvironment, drug resistance frequently emerges, thereby substantially influencing the effectiveness of HER2-targeted therapy. This article comprehensively summarizes and deliberates upon the strategies of HER2-targeted therapy as well as the underlying resistance mechanisms.
MEMBER ACCOUNT
登录成功会直接打开下一页。
